EdiGene startup to focus on gene therapy of orphan diseases
The company is a spin-off of the University of Tokyo, using the research results of Osamu NUREKI. They develop in vivo gene therapy using adeno-associated virus (AAV) vectors for single gene diseases.
EdiGene startup to focus on gene therapy of orphan diseases
The company is a spin-off of the University of Tokyo, using the research results of Osamu NUREKI. They develop in vivo gene therapy using adeno-associated virus (AAV) vectors for single gene diseases. https://www.j-startup.go.jp/en/startups/017_edigene.html
read moreGene Techno Science to develop dental pulp-derived stem cells for treatment of childrens’ diseases
Gene Technos Science Co. shareholders have approved to make Cell Technology, acquired in January 2019, a wholly-owned subsidiary. Cell Technology has a partnership with over 2000 medical institutions across Japan to provide services for dental pulp-derived and other...
read moreRIKEN and Hitachi succeed in automated culture of retinal pigment epithelial (RPE) cell sheets derived from human iPS cells
A joint research team of Hitachi and RIKEN have successfully used a completely closed automatic cell culture system for culturing RPE cell sheets derived from human iPS cells. using a culture device. By analysis of various markers it was demonstrated that...
read moreRIKEN researchers prepare adhesive silk by tyrosinase-catalysed oxidation
Hiromitsu SUGAKAWA and colleagues at RIKEN Bioresources Research Center have treated an aqueous silk protein solution with tyrosinase, thereby converting tyrosine residues in silk to DOPA. Amino acid analysis by ninhydrin confirmed that the treated silk contained...
read moreOlympus launches endoscope software “EndoBRAIN” based on AI data
The imaging system will help to judge wheter a polyp detected by the endoscope is neoplastic or not. It has obtained regulatory domestic approval for sales in Japan. Nikkei Biotech news release, March 4, 2019 +
read moreToMMo publishs JG1, the “Japanese Reference Genome Sequence”
ToMMO, the Tohoku Medical MegaBank Organization, is focused on genomic medicine, which requires to accurately analyze the genome sequence of individuals based on differences to a "reference genomic sequence". As the “international reference genome” was created based...
read moreMHLW approves two gene therapies in Japan
The two items approved were Anges Co. HGF gene therapy for treatment of critical limb ischemia (AMG0001, beperminogene perplasmid)Novartis CAR-T cell therapy Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic B-cell leukemia Nikkei Biotech news...
read moreVIGO Medical Co. to test effect of pure oxygen supply with major Japanese football club
In a cooperative project with NEDO, the company will supply its Oxy's® oxygen generator to Japan First League Oita Trinita players for a year and perform blood tests of athletes' vital measurements (body temperature, blood pressure, heart rate, mileage, number of...
read moreKeio University team to start application of regenerative medicine for subacute spinal cord injury
Professor Ekuo OKANO of Keio University School of Medicine and colleagues have obtained MHLW approval for clinical studies on allogenic iPS cell-derived neural progenitor cells for the treatment of subacute stage spinal cord injury. They will now investigate the...
read moreUniversity team develops methane dry reforming catalyst for operation at 500 C
The team at Kochi University and Tokyo University of Technology succeeded to develop a Ni / Y 2 O 3 catalyst which allows to produce synthesis gas from methane and CO at below 600 C without coking. The catalyst is composed of Ni and Y2O3 which are topological...
read moreTanabe Mitsubishi turns product development over to venture company
Mitsubishi Tanabe announced that phase I of its antibody-drug complex MT-8633 against solid cancer will be carried out by Open Innovation Partners, a Tokyo-based venture. It is believed that this move is meant to raise development speed. Tanabe-Mitsubishi Pharma news...
read moreDaiichi Sankyo to apply for approval of gene therapy for cancer treatment
The application for domestic manufacturing and marketing is based on a doctor-based interim analysis of 13 subjects (corresponding to phase II) with the oncolytic herpes simplex virus vector G47Δwhich showed a 92.3 % survival rate. Nikkei Biotech news release,...
read more